AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
tranexamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2713 | 1197-18-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antifibrinolytic hemostatic used in severe hemorrhage.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
| 2 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 34 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.38 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.97 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.30 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 31 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.788 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.694 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.964 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.692 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 81.850 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 75.380 | % | High | 1 |
| herg | hERG pIC50 | 5.143 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.472 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.614 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 81.430 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PRKDC,SYK,TEK,TGFBR1 | 25 | |||
| kinase-selectivity-class | EIF2AK3,MAP2K6 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.262 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.563 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 87.570 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.279 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 83.560 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 2.972 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 81.710 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 94.320 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 843.335 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1986 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myoclonus | 134.99 | 14.98 | 65 | 14840 | 19103 | 90594439 |
| Aplastic anaemia | 131.26 | 14.98 | 57 | 14848 | 13212 | 90600330 |
| Renal cortical necrosis | 130.52 | 14.98 | 25 | 14880 | 278 | 90613264 |
| Wrong product administered | 124.40 | 14.98 | 47 | 14858 | 7618 | 90605924 |
| Pulmonary embolism | 106.37 | 14.98 | 119 | 14786 | 130701 | 90482841 |
| Generalised tonic-clonic seizure | 98.61 | 14.98 | 65 | 14840 | 34838 | 90578704 |
| Anaphylactic reaction | 96.99 | 14.98 | 94 | 14811 | 87430 | 90526112 |
| Vaginal haemorrhage | 95.12 | 14.98 | 61 | 14844 | 31210 | 90582332 |
| Melaena | 91.56 | 14.98 | 62 | 14843 | 34735 | 90578807 |
| Hereditary angioedema | 88.62 | 14.98 | 39 | 14866 | 9326 | 90604216 |
| Haemorrhage | 83.50 | 14.98 | 78 | 14827 | 69291 | 90544251 |
| Purpura | 80.17 | 14.98 | 42 | 14863 | 14736 | 90598806 |
| Heavy menstrual bleeding | 74.98 | 14.98 | 45 | 14860 | 20485 | 90593057 |
| Platelet count decreased | 73.28 | 14.98 | 101 | 14804 | 136868 | 90476674 |
| Seizure | 72.02 | 14.98 | 106 | 14799 | 152523 | 90461019 |
| Maternal exposure during delivery | 71.27 | 14.98 | 26 | 14879 | 3820 | 90609722 |
| Status epilepticus | 67.97 | 14.98 | 41 | 14864 | 18833 | 90594709 |
| Deep vein thrombosis | 55.79 | 14.98 | 72 | 14833 | 91548 | 90521994 |
| Hypotension | 55.35 | 14.98 | 147 | 14758 | 325250 | 90288292 |
| Cerebral venous sinus thrombosis | 55.20 | 14.98 | 19 | 14886 | 2357 | 90611185 |
| Rash maculo-papular | 53.08 | 14.98 | 48 | 14857 | 40885 | 90572657 |
| Cerebral infarction | 52.94 | 14.98 | 40 | 14865 | 26556 | 90586986 |
| Vasodilatation | 51.60 | 14.98 | 19 | 14886 | 2865 | 90610677 |
| Cardiac arrest | 51.10 | 14.98 | 74 | 14831 | 104861 | 90508681 |
| Tachycardia | 50.58 | 14.98 | 92 | 14813 | 157581 | 90455961 |
| Joint swelling | 49.75 | 14.98 | 11 | 14894 | 503289 | 90110253 |
| Thrombocytopenia | 49.15 | 14.98 | 107 | 14798 | 208618 | 90404924 |
| Febrile neutropenia | 47.79 | 14.98 | 90 | 14815 | 158259 | 90455283 |
| Anaphylactic shock | 44.82 | 14.98 | 39 | 14866 | 31578 | 90581964 |
| Alopecia | 44.73 | 14.98 | 13 | 14892 | 495058 | 90118484 |
| Fatigue | 44.68 | 14.98 | 76 | 14829 | 1153947 | 89459595 |
| Angioedema | 44.30 | 14.98 | 54 | 14851 | 64822 | 90548720 |
| Drug hypersensitivity | 44.09 | 14.98 | 11 | 14894 | 463598 | 90149944 |
| Acute myocardial infarction | 43.45 | 14.98 | 40 | 14865 | 34850 | 90578692 |
| Transfusion | 43.24 | 14.98 | 30 | 14875 | 17458 | 90596084 |
| Off label use | 43.21 | 14.98 | 319 | 14586 | 1101933 | 89511609 |
| Uterine haemorrhage | 42.42 | 14.98 | 19 | 14886 | 4733 | 90608809 |
| Systemic lupus erythematosus | 42.23 | 14.98 | 5 | 14900 | 361891 | 90251651 |
| Ovarian vein thrombosis | 41.93 | 14.98 | 8 | 14897 | 87 | 90613455 |
| Drug intolerance | 41.83 | 14.98 | 11 | 14894 | 447580 | 90165962 |
| Myoclonic epilepsy | 41.68 | 14.98 | 14 | 14891 | 1613 | 90611929 |
| Incorrect route of product administration | 41.00 | 14.98 | 46 | 14859 | 50580 | 90562962 |
| Biliary sepsis | 39.82 | 14.98 | 12 | 14893 | 974 | 90612568 |
| Hepatic function abnormal | 39.10 | 14.98 | 43 | 14862 | 46245 | 90567297 |
| Epistaxis | 38.51 | 14.98 | 58 | 14847 | 85067 | 90528475 |
| Enterococcal sepsis | 37.84 | 14.98 | 13 | 14892 | 1603 | 90611939 |
| Shock haemorrhagic | 37.50 | 14.98 | 24 | 14881 | 12221 | 90601321 |
| Brain oedema | 36.50 | 14.98 | 27 | 14878 | 17358 | 90596184 |
| Contraindicated product administered | 35.96 | 14.98 | 5 | 14900 | 320134 | 90293408 |
| Rheumatoid arthritis | 35.66 | 14.98 | 8 | 14897 | 362606 | 90250936 |
| Neutropenic sepsis | 35.49 | 14.98 | 27 | 14878 | 18103 | 90595439 |
| Haemoptysis | 35.41 | 14.98 | 35 | 14870 | 33285 | 90580257 |
| Product packaging confusion | 34.77 | 14.98 | 8 | 14897 | 225 | 90613317 |
| Rash erythematous | 34.77 | 14.98 | 48 | 14857 | 65056 | 90548486 |
| Mucosal inflammation | 34.62 | 14.98 | 45 | 14860 | 57580 | 90555962 |
| Abdominal discomfort | 34.12 | 14.98 | 18 | 14887 | 477310 | 90136232 |
| Retinal artery occlusion | 33.53 | 14.98 | 13 | 14892 | 2258 | 90611284 |
| Pericarditis | 33.40 | 14.98 | 3 | 14902 | 270148 | 90343394 |
| Sepsis | 33.37 | 14.98 | 84 | 14821 | 179730 | 90433812 |
| Haemoglobin decreased | 32.53 | 14.98 | 78 | 14827 | 161878 | 90451664 |
| Infusion related reaction | 32.41 | 14.98 | 14 | 14891 | 416766 | 90196776 |
| Ureteric perforation | 31.89 | 14.98 | 5 | 14900 | 14 | 90613528 |
| Puncture site haematoma | 31.46 | 14.98 | 6 | 14899 | 65 | 90613477 |
| Blood pressure decreased | 31.02 | 14.98 | 49 | 14856 | 74846 | 90538696 |
| Drug ineffective for unapproved indication | 30.98 | 14.98 | 46 | 14859 | 66598 | 90546944 |
| Haemorrhage intracranial | 30.61 | 14.98 | 23 | 14882 | 15139 | 90598403 |
| Tri-iodothyronine free decreased | 30.42 | 14.98 | 8 | 14897 | 395 | 90613147 |
| Tonic clonic movements | 29.54 | 14.98 | 11 | 14894 | 1711 | 90611831 |
| Pain | 28.97 | 14.98 | 77 | 14828 | 996264 | 89617278 |
| Toxic epidermal necrolysis | 28.84 | 14.98 | 31 | 14874 | 32497 | 90581045 |
| Ischaemic stroke | 28.74 | 14.98 | 26 | 14879 | 22140 | 90591402 |
| Acute left ventricular failure | 28.70 | 14.98 | 10 | 14895 | 1286 | 90612256 |
| Nosocomial infection | 28.42 | 14.98 | 11 | 14894 | 1902 | 90611640 |
| Alanine aminotransferase increased | 28.21 | 14.98 | 61 | 14844 | 118277 | 90495265 |
| Acute generalised exanthematous pustulosis | 28.14 | 14.98 | 21 | 14884 | 13682 | 90599860 |
| Infusion site scar | 27.19 | 14.98 | 8 | 14897 | 598 | 90612944 |
| Haemorrhagic disorder | 27.08 | 14.98 | 9 | 14896 | 1003 | 90612539 |
| Stridor | 27.07 | 14.98 | 14 | 14891 | 4779 | 90608763 |
| Psoriatic arthropathy | 27.01 | 14.98 | 3 | 14902 | 228332 | 90385210 |
| Pulmonary alveolar haemorrhage | 26.82 | 14.98 | 15 | 14890 | 5983 | 90607559 |
| Anaemia | 26.09 | 14.98 | 121 | 14784 | 352681 | 90260861 |
| Coronary artery thrombosis | 26.02 | 14.98 | 9 | 14896 | 1133 | 90612409 |
| Basophil count increased | 25.95 | 14.98 | 9 | 14896 | 1142 | 90612400 |
| Puncture site haemorrhage | 25.77 | 14.98 | 7 | 14898 | 391 | 90613151 |
| Mobility decreased | 25.73 | 14.98 | 5 | 14900 | 250729 | 90362813 |
| Uterine disorder | 25.70 | 14.98 | 12 | 14893 | 3289 | 90610253 |
| Factor VII deficiency | 25.45 | 14.98 | 5 | 14900 | 64 | 90613478 |
| Urine ketone body present | 25.35 | 14.98 | 11 | 14894 | 2541 | 90611001 |
| Multiple organ dysfunction syndrome | 24.64 | 14.98 | 42 | 14863 | 68294 | 90545248 |
| Perforation | 24.51 | 14.98 | 10 | 14895 | 1984 | 90611558 |
| Asthma | 24.49 | 14.98 | 5 | 14900 | 242155 | 90371387 |
| Platelet count increased | 24.21 | 14.98 | 23 | 14882 | 20836 | 90592706 |
| Haemodynamic instability | 24.13 | 14.98 | 18 | 14887 | 11721 | 90601821 |
| Weight increased | 24.12 | 14.98 | 20 | 14885 | 417907 | 90195635 |
| Electrocardiogram PR shortened | 23.65 | 14.98 | 7 | 14898 | 534 | 90613008 |
| Poor venous access | 23.56 | 14.98 | 22 | 14883 | 19505 | 90594037 |
| Cancer pain | 23.44 | 14.98 | 12 | 14893 | 4013 | 90609529 |
| Atrial thrombosis | 23.36 | 14.98 | 10 | 14895 | 2235 | 90611307 |
| Embolic stroke | 23.30 | 14.98 | 12 | 14893 | 4060 | 90609482 |
| Uterine leiomyoma | 23.09 | 14.98 | 17 | 14888 | 10847 | 90602695 |
| Premature delivery | 22.86 | 14.98 | 30 | 14875 | 38732 | 90574810 |
| Postpartum haemorrhage | 22.72 | 14.98 | 10 | 14895 | 2391 | 90611151 |
| Circulatory collapse | 22.54 | 14.98 | 24 | 14881 | 24880 | 90588662 |
| Thrombosis | 22.53 | 14.98 | 42 | 14863 | 73209 | 90540333 |
| Platelet transfusion | 22.36 | 14.98 | 8 | 14897 | 1112 | 90612430 |
| Product dose omission issue | 22.34 | 14.98 | 10 | 14895 | 291677 | 90321865 |
| Wound | 22.26 | 14.98 | 11 | 14894 | 302969 | 90310573 |
| Urinary tract disorder | 21.42 | 14.98 | 11 | 14894 | 3700 | 90609842 |
| Rectal haemorrhage | 21.27 | 14.98 | 44 | 14861 | 82700 | 90530842 |
| Type 2 diabetes mellitus | 20.96 | 14.98 | 4 | 14901 | 203240 | 90410302 |
| Extravasation | 20.70 | 14.98 | 10 | 14895 | 2954 | 90610588 |
| Pulmonary haemorrhage | 20.41 | 14.98 | 14 | 14891 | 7999 | 90605543 |
| Infusion site warmth | 20.38 | 14.98 | 9 | 14896 | 2169 | 90611373 |
| Hypoventilation | 20.35 | 14.98 | 12 | 14893 | 5284 | 90608258 |
| Coagulopathy | 20.30 | 14.98 | 22 | 14883 | 23267 | 90590275 |
| Memory impairment | 20.09 | 14.98 | 4 | 14901 | 197240 | 90416302 |
| Meningitis aseptic | 20.06 | 14.98 | 13 | 14892 | 6760 | 90606782 |
| Stress cardiomyopathy | 19.99 | 14.98 | 17 | 14888 | 13338 | 90600204 |
| Hepatic enzyme increased | 19.92 | 14.98 | 18 | 14887 | 360718 | 90252824 |
| Gastrointestinal haemorrhage | 19.79 | 14.98 | 45 | 14860 | 90203 | 90523339 |
| Blood cholesterol increased | 19.62 | 14.98 | 5 | 14900 | 208007 | 90405535 |
| Impaired healing | 19.61 | 14.98 | 7 | 14898 | 234192 | 90379350 |
| Fibroma | 19.59 | 14.98 | 7 | 14898 | 969 | 90612573 |
| Arterial thrombosis | 19.58 | 14.98 | 8 | 14897 | 1592 | 90611950 |
| Stevens-Johnson syndrome | 19.31 | 14.98 | 24 | 14881 | 29352 | 90584190 |
| Disinhibition | 18.97 | 14.98 | 7 | 14898 | 1061 | 90612481 |
| Infusion site discomfort | 18.60 | 14.98 | 8 | 14897 | 1808 | 90611734 |
| Lower respiratory tract infection | 18.56 | 14.98 | 9 | 14896 | 250650 | 90362892 |
| Drug interaction | 18.38 | 14.98 | 92 | 14813 | 276361 | 90337181 |
| Injury | 18.13 | 14.98 | 5 | 14900 | 197344 | 90416198 |
| Sinusitis | 17.91 | 14.98 | 18 | 14887 | 343070 | 90270472 |
| Ischaemia | 17.77 | 14.98 | 11 | 14894 | 5284 | 90608258 |
| Cerebral haemorrhage | 17.75 | 14.98 | 25 | 14880 | 34497 | 90579045 |
| Toxic skin eruption | 17.56 | 14.98 | 17 | 14888 | 15757 | 90597785 |
| Fibromyalgia | 17.56 | 14.98 | 6 | 14899 | 206263 | 90407279 |
| Uterine atony | 17.41 | 14.98 | 5 | 14900 | 343 | 90613199 |
| Venous thrombosis | 17.32 | 14.98 | 11 | 14894 | 5526 | 90608016 |
| Ventricular fibrillation | 17.28 | 14.98 | 16 | 14889 | 14028 | 90599514 |
| Asthenia | 17.22 | 14.98 | 39 | 14866 | 533712 | 90079830 |
| Allergic reaction to excipient | 17.14 | 14.98 | 6 | 14899 | 782 | 90612760 |
| Enterocolitis | 17.04 | 14.98 | 14 | 14891 | 10476 | 90603066 |
| Caesarean section | 16.99 | 14.98 | 18 | 14887 | 18559 | 90594983 |
| PCO2 abnormal | 16.98 | 14.98 | 4 | 14901 | 125 | 90613417 |
| Drug ineffective | 16.90 | 14.98 | 320 | 14585 | 1383978 | 89229564 |
| Hyperaesthesia | 16.80 | 14.98 | 14 | 14891 | 10688 | 90602854 |
| Acute respiratory distress syndrome | 16.60 | 14.98 | 22 | 14883 | 28664 | 90584878 |
| Nasopharyngitis | 16.42 | 14.98 | 26 | 14879 | 407078 | 90206464 |
| Ill-defined disorder | 16.40 | 14.98 | 5 | 14900 | 184886 | 90428656 |
| Dry mouth | 16.29 | 14.98 | 5 | 14900 | 184054 | 90429488 |
| Infusion site rash | 16.21 | 14.98 | 8 | 14897 | 2475 | 90611067 |
| Pancytopenia | 16.18 | 14.98 | 50 | 14855 | 120213 | 90493329 |
| Arterial haemorrhage | 16.09 | 14.98 | 8 | 14897 | 2515 | 90611027 |
| Discomfort | 15.98 | 14.98 | 13 | 14892 | 274322 | 90339220 |
| HER2 positive breast cancer | 15.93 | 14.98 | 5 | 14900 | 465 | 90613077 |
| Thoracotomy | 15.69 | 14.98 | 3 | 14902 | 33 | 90613509 |
| Upper respiratory tract inflammation | 15.66 | 14.98 | 8 | 14897 | 2664 | 90610878 |
| False negative investigation result | 15.50 | 14.98 | 4 | 14901 | 183 | 90613359 |
| Upper gastrointestinal haemorrhage | 15.47 | 14.98 | 19 | 14886 | 22957 | 90590585 |
| Acute myeloid leukaemia | 15.43 | 14.98 | 18 | 14887 | 20622 | 90592920 |
| Adnexal torsion | 15.30 | 14.98 | 5 | 14900 | 529 | 90613013 |
| Blood lactate dehydrogenase increased | 15.18 | 14.98 | 20 | 14885 | 25912 | 90587630 |
| Colitis ischaemic | 15.07 | 14.98 | 14 | 14891 | 12332 | 90601210 |
| Psoriasis | 15.04 | 14.98 | 3 | 14902 | 147751 | 90465791 |
| Shock | 15.03 | 14.98 | 21 | 14884 | 28757 | 90584785 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 147.92 | 16.84 | 109 | 11374 | 42634 | 42567218 |
| Haemorrhage | 142.27 | 16.84 | 123 | 11360 | 60440 | 42549412 |
| Myoclonus | 111.93 | 16.84 | 65 | 11418 | 17000 | 42592852 |
| Factor VIII inhibition | 88.91 | 16.84 | 20 | 11463 | 302 | 42609550 |
| Mechanical ventilation complication | 87.57 | 16.84 | 23 | 11460 | 681 | 42609171 |
| Febrile neutropenia | 86.14 | 16.84 | 168 | 11315 | 185535 | 42424317 |
| Haemothorax | 75.66 | 16.84 | 34 | 11449 | 5202 | 42604650 |
| Wrong product administered | 73.06 | 16.84 | 35 | 11448 | 6191 | 42603661 |
| Haemarthrosis | 67.61 | 16.84 | 29 | 11454 | 3969 | 42605883 |
| Generalised tonic-clonic seizure | 66.81 | 16.84 | 56 | 11427 | 26323 | 42583529 |
| Anaphylactic shock | 66.01 | 16.84 | 53 | 11430 | 23464 | 42586388 |
| Aplastic anaemia | 62.75 | 16.84 | 40 | 11443 | 12344 | 42597508 |
| Inspiratory capacity decreased | 58.47 | 16.84 | 24 | 11459 | 2943 | 42606909 |
| Shock haemorrhagic | 52.94 | 16.84 | 40 | 11443 | 16202 | 42593650 |
| Vasodilatation | 49.66 | 16.84 | 17 | 11466 | 1260 | 42608592 |
| Adverse reaction | 48.53 | 16.84 | 23 | 11460 | 3970 | 42605882 |
| Status epilepticus | 47.78 | 16.84 | 37 | 11446 | 15541 | 42594311 |
| Post procedural haemorrhage | 46.98 | 16.84 | 30 | 11453 | 9282 | 42600570 |
| Post procedural hypotension | 45.45 | 16.84 | 9 | 11474 | 70 | 42609782 |
| Muscle haemorrhage | 44.81 | 16.84 | 22 | 11461 | 4103 | 42605749 |
| Vascular stent thrombosis | 43.51 | 16.84 | 20 | 11463 | 3222 | 42606630 |
| Cerebral infarction | 42.41 | 16.84 | 47 | 11436 | 31122 | 42578730 |
| Angiopathy | 42.06 | 16.84 | 23 | 11460 | 5354 | 42604498 |
| Epistaxis | 41.82 | 16.84 | 69 | 11414 | 66757 | 42543095 |
| Mucosal inflammation | 39.33 | 16.84 | 57 | 11426 | 49317 | 42560535 |
| Tachycardia | 39.12 | 16.84 | 85 | 11398 | 101002 | 42508850 |
| Platelet count decreased | 39.05 | 16.84 | 103 | 11380 | 138478 | 42471374 |
| Urticaria | 35.45 | 16.84 | 68 | 11415 | 73968 | 42535884 |
| Face oedema | 34.56 | 16.84 | 29 | 11454 | 13637 | 42596215 |
| Myoclonic epilepsy | 34.55 | 16.84 | 14 | 11469 | 1660 | 42608192 |
| Emphysema | 33.89 | 16.84 | 27 | 11456 | 11808 | 42598044 |
| Hypovolaemia | 32.46 | 16.84 | 26 | 11457 | 11459 | 42598393 |
| Haemophilia | 32.16 | 16.84 | 5 | 11478 | 6 | 42609846 |
| Fatigue | 31.44 | 16.84 | 43 | 11440 | 435598 | 42174254 |
| Pneumothorax | 31.16 | 16.84 | 35 | 11448 | 23508 | 42586344 |
| Mesenteric vascular insufficiency | 31.10 | 16.84 | 7 | 11476 | 106 | 42609746 |
| Coronary artery thrombosis | 30.36 | 16.84 | 14 | 11469 | 2272 | 42607580 |
| Incorrect route of product administration | 30.25 | 16.84 | 35 | 11448 | 24270 | 42585582 |
| Upper respiratory tract inflammation | 29.60 | 16.84 | 13 | 11470 | 1883 | 42607969 |
| Interstitial lung disease | 29.24 | 16.84 | 65 | 11418 | 78397 | 42531455 |
| Product dose omission issue | 28.28 | 16.84 | 4 | 11479 | 154361 | 42455491 |
| Haemoptysis | 25.35 | 16.84 | 45 | 11438 | 46122 | 42563730 |
| Platelet transfusion | 24.47 | 16.84 | 11 | 11472 | 1683 | 42608169 |
| Gingival bleeding | 23.53 | 16.84 | 19 | 11464 | 8466 | 42601386 |
| Hypotension | 23.08 | 16.84 | 133 | 11350 | 257498 | 42352354 |
| Hepatic function abnormal | 23.01 | 16.84 | 46 | 11437 | 51521 | 42558331 |
| Pulmonary haemorrhage | 22.46 | 16.84 | 21 | 11462 | 11376 | 42598476 |
| Inhibiting antibodies positive | 21.66 | 16.84 | 3 | 11480 | 0 | 42609852 |
| Tryptase decreased | 21.10 | 16.84 | 4 | 11479 | 24 | 42609828 |
| Immune thrombocytopenia | 20.83 | 16.84 | 20 | 11463 | 11196 | 42598656 |
| Gastrointestinal haemorrhage | 20.14 | 16.84 | 65 | 11418 | 97661 | 42512191 |
| Haemoglobin increased | 19.62 | 16.84 | 14 | 11469 | 5192 | 42604660 |
| Chronic pulmonary histoplasmosis | 19.58 | 16.84 | 3 | 11480 | 3 | 42609849 |
| Clonus | 19.41 | 16.84 | 12 | 11471 | 3508 | 42606344 |
| Toxicity to various agents | 19.27 | 16.84 | 20 | 11463 | 229116 | 42380736 |
| Bronchospasm | 18.51 | 16.84 | 20 | 11463 | 12865 | 42596987 |
| Acute myocardial infarction | 18.18 | 16.84 | 45 | 11438 | 58120 | 42551732 |
| Labile blood pressure | 18.08 | 16.84 | 7 | 11476 | 736 | 42609116 |
| Pneumonia | 17.98 | 16.84 | 183 | 11300 | 421966 | 42187886 |
| Haemorrhagic diathesis | 17.91 | 16.84 | 11 | 11472 | 3178 | 42606674 |
| Pleural effusion | 17.69 | 16.84 | 62 | 11421 | 97104 | 42512748 |
| Hepatic cyst ruptured | 17.50 | 16.84 | 3 | 11480 | 9 | 42609843 |
| Death | 17.29 | 16.84 | 67 | 11416 | 471118 | 42138734 |
| Fibrin degradation products increased | 16.95 | 16.84 | 5 | 11478 | 228 | 42609624 |
| Nystagmus | 16.94 | 16.84 | 13 | 11470 | 5383 | 42604469 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 233.37 | 13.62 | 199 | 24846 | 114101 | 110450153 |
| Myoclonus | 212.57 | 13.62 | 117 | 24928 | 32881 | 110531373 |
| Haemorrhage | 208.14 | 13.62 | 181 | 24864 | 106511 | 110457743 |
| Wrong product administered | 196.97 | 13.62 | 79 | 24966 | 10881 | 110553373 |
| Aplastic anaemia | 184.10 | 13.62 | 96 | 24949 | 24212 | 110540042 |
| Generalised tonic-clonic seizure | 167.43 | 13.62 | 121 | 24924 | 54559 | 110509695 |
| Renal cortical necrosis | 108.89 | 13.62 | 25 | 25020 | 499 | 110563755 |
| Status epilepticus | 108.52 | 13.62 | 75 | 24970 | 31496 | 110532758 |
| Febrile neutropenia | 107.87 | 13.62 | 228 | 24817 | 316539 | 110247715 |
| Anaphylactic shock | 107.67 | 13.62 | 91 | 24954 | 51455 | 110512799 |
| Platelet count decreased | 104.21 | 13.62 | 187 | 24858 | 230256 | 110333998 |
| Vasodilatation | 99.82 | 13.62 | 36 | 25009 | 3708 | 110560546 |
| Mechanical ventilation complication | 89.44 | 13.62 | 23 | 25022 | 748 | 110563506 |
| Shock haemorrhagic | 87.29 | 13.62 | 62 | 24983 | 27185 | 110537069 |
| Cerebral infarction | 87.29 | 13.62 | 81 | 24964 | 51757 | 110512497 |
| Haemothorax | 84.17 | 13.62 | 38 | 25007 | 6993 | 110557261 |
| Hereditary angioedema | 83.74 | 13.62 | 38 | 25007 | 7076 | 110557178 |
| Myoclonic epilepsy | 79.79 | 13.62 | 28 | 25017 | 2663 | 110561591 |
| Factor VIII inhibition | 79.74 | 13.62 | 18 | 25027 | 332 | 110563922 |
| Tachycardia | 76.93 | 13.62 | 163 | 24882 | 226482 | 110337772 |
| Vaginal haemorrhage | 73.35 | 13.62 | 54 | 24991 | 25020 | 110539234 |
| Melaena | 71.56 | 13.62 | 83 | 24962 | 68674 | 110495580 |
| Epistaxis | 71.04 | 13.62 | 115 | 24930 | 130257 | 110433997 |
| Fatigue | 69.72 | 13.62 | 105 | 24940 | 1215853 | 109348401 |
| Pulmonary embolism | 69.05 | 13.62 | 151 | 24894 | 214323 | 110349931 |
| Inspiratory capacity decreased | 65.63 | 13.62 | 24 | 25021 | 2571 | 110561683 |
| Mucosal inflammation | 65.36 | 13.62 | 94 | 24951 | 96047 | 110468207 |
| Maternal exposure during delivery | 61.64 | 13.62 | 25 | 25020 | 3540 | 110560714 |
| Haemarthrosis | 61.42 | 13.62 | 31 | 25014 | 7298 | 110556956 |
| Incorrect route of product administration | 61.15 | 13.62 | 74 | 24971 | 63987 | 110500267 |
| Seizure | 60.46 | 13.62 | 146 | 24899 | 221039 | 110343215 |
| Heavy menstrual bleeding | 58.89 | 13.62 | 40 | 25005 | 16325 | 110547929 |
| Hypotension | 57.60 | 13.62 | 253 | 24792 | 523596 | 110040658 |
| Acute myocardial infarction | 57.08 | 13.62 | 82 | 24963 | 83695 | 110480559 |
| Coronary artery thrombosis | 56.95 | 13.62 | 23 | 25022 | 3221 | 110561033 |
| Post procedural hypotension | 56.32 | 13.62 | 11 | 25034 | 96 | 110564158 |
| Hepatic function abnormal | 55.92 | 13.62 | 84 | 24961 | 89211 | 110475043 |
| Drug intolerance | 55.74 | 13.62 | 12 | 25033 | 406500 | 110157754 |
| Haemoptysis | 54.82 | 13.62 | 74 | 24971 | 71280 | 110492974 |
| Purpura | 52.86 | 13.62 | 44 | 25001 | 24344 | 110539910 |
| Joint swelling | 51.51 | 13.62 | 18 | 25027 | 442827 | 110121427 |
| Synovitis | 50.05 | 13.62 | 3 | 25042 | 274089 | 110290165 |
| Arthropathy | 50.03 | 13.62 | 4 | 25041 | 287518 | 110276736 |
| Rash maculo-papular | 49.61 | 13.62 | 72 | 24973 | 74150 | 110490104 |
| Post procedural haemorrhage | 48.99 | 13.62 | 35 | 25010 | 15477 | 110548777 |
| Drug hypersensitivity | 47.04 | 13.62 | 22 | 25023 | 454068 | 110110186 |
| Platelet transfusion | 45.94 | 13.62 | 19 | 25026 | 2827 | 110561427 |
| Deep vein thrombosis | 45.58 | 13.62 | 99 | 24946 | 139788 | 110424466 |
| Cardiac arrest | 44.55 | 13.62 | 121 | 24924 | 196632 | 110367622 |
| Alopecia | 43.85 | 13.62 | 14 | 25031 | 364739 | 110199515 |
| Drug ineffective | 43.59 | 13.62 | 530 | 24515 | 1520010 | 109044244 |
| Muscle haemorrhage | 43.23 | 13.62 | 24 | 25021 | 6845 | 110557409 |
| Cerebral venous sinus thrombosis | 42.29 | 13.62 | 18 | 25027 | 2877 | 110561377 |
| Uterine haemorrhage | 42.19 | 13.62 | 19 | 25026 | 3475 | 110560779 |
| Product packaging confusion | 42.19 | 13.62 | 11 | 25034 | 378 | 110563876 |
| Product dose omission issue | 41.15 | 13.62 | 11 | 25034 | 321771 | 110242483 |
| Rheumatoid arthritis | 40.74 | 13.62 | 9 | 25036 | 299604 | 110264650 |
| Angiopathy | 40.42 | 13.62 | 25 | 25020 | 8705 | 110555549 |
| Blood pressure decreased | 39.27 | 13.62 | 83 | 24962 | 115008 | 110449246 |
| Upper respiratory tract inflammation | 38.13 | 13.62 | 19 | 25026 | 4352 | 110559902 |
| Systemic lupus erythematosus | 38.08 | 13.62 | 6 | 25039 | 254332 | 110309922 |
| Vascular stent thrombosis | 36.04 | 13.62 | 18 | 25027 | 4143 | 110560111 |
| Pericarditis | 35.59 | 13.62 | 4 | 25041 | 219110 | 110345144 |
| Asthma | 35.09 | 13.62 | 7 | 25038 | 250284 | 110313970 |
| Pain | 34.93 | 13.62 | 106 | 24939 | 954849 | 109609405 |
| Infusion related reaction | 34.33 | 13.62 | 22 | 25023 | 381140 | 110183114 |
| Ovarian vein thrombosis | 34.29 | 13.62 | 7 | 25038 | 78 | 110564176 |
| Pulmonary haemorrhage | 34.24 | 13.62 | 29 | 25016 | 16427 | 110547827 |
| Thrombocytopenia | 34.19 | 13.62 | 163 | 24882 | 348722 | 110215532 |
| Transfusion | 33.89 | 13.62 | 35 | 25010 | 25437 | 110538817 |
| Immune thrombocytopenia | 33.77 | 13.62 | 33 | 25012 | 22461 | 110541793 |
| Gastrointestinal haemorrhage | 33.74 | 13.62 | 98 | 24947 | 165420 | 110398834 |
| Drug ineffective for unapproved indication | 33.74 | 13.62 | 73 | 24972 | 102765 | 110461489 |
| Hypovolaemia | 32.92 | 13.62 | 32 | 25013 | 21642 | 110542612 |
| Retinal artery occlusion | 32.79 | 13.62 | 17 | 25028 | 4232 | 110560022 |
| Stridor | 32.57 | 13.62 | 20 | 25025 | 6875 | 110557379 |
| Face oedema | 32.49 | 13.62 | 39 | 25006 | 33430 | 110530824 |
| Pneumothorax | 32.43 | 13.62 | 40 | 25005 | 35245 | 110529009 |
| Tonic clonic movements | 32.33 | 13.62 | 15 | 25030 | 2937 | 110561317 |
| Dry mouth | 31.61 | 13.62 | 4 | 25041 | 199944 | 110364310 |
| Cerebral haemorrhage | 30.96 | 13.62 | 54 | 24991 | 64914 | 110499340 |
| Enterococcal sepsis | 30.69 | 13.62 | 15 | 25030 | 3297 | 110560957 |
| Mesenteric vascular insufficiency | 30.62 | 13.62 | 7 | 25038 | 137 | 110564117 |
| Mobility decreased | 30.57 | 13.62 | 8 | 25037 | 237414 | 110326840 |
| Shock | 30.16 | 13.62 | 48 | 24997 | 53540 | 110510714 |
| Asthenia | 30.07 | 13.62 | 70 | 24975 | 688929 | 109875325 |
| Haemodynamic instability | 29.64 | 13.62 | 31 | 25014 | 22857 | 110541397 |
| Ureteric perforation | 29.56 | 13.62 | 5 | 25040 | 17 | 110564237 |
| Acute generalised exanthematous pustulosis | 29.24 | 13.62 | 30 | 25015 | 21634 | 110542620 |
| Off label use | 28.91 | 13.62 | 488 | 24557 | 1499697 | 109064557 |
| Abdominal discomfort | 28.83 | 13.62 | 28 | 25017 | 393830 | 110170424 |
| Drug eruption | 28.75 | 13.62 | 47 | 24998 | 53612 | 110510642 |
| Biliary sepsis | 28.72 | 13.62 | 12 | 25033 | 1831 | 110562423 |
| Neutropenic sepsis | 28.50 | 13.62 | 35 | 25010 | 30711 | 110533543 |
| Weight increased | 28.28 | 13.62 | 32 | 25013 | 419612 | 110144642 |
| Angioedema | 27.94 | 13.62 | 66 | 24979 | 98434 | 110465820 |
| Interstitial lung disease | 27.92 | 13.62 | 82 | 24963 | 139252 | 110425002 |
| Platelet count increased | 27.74 | 13.62 | 32 | 25013 | 26302 | 110537952 |
| Haemoglobin increased | 27.43 | 13.62 | 20 | 25025 | 9127 | 110555127 |
| Infusion site scar | 27.26 | 13.62 | 8 | 25037 | 428 | 110563826 |
| Factor VII deficiency | 27.04 | 13.62 | 6 | 25039 | 102 | 110564152 |
| Injury | 26.95 | 13.62 | 4 | 25041 | 177261 | 110386993 |
| Tri-iodothyronine free decreased | 26.85 | 13.62 | 8 | 25037 | 451 | 110563803 |
| Brain oedema | 26.59 | 13.62 | 34 | 25011 | 31064 | 110533190 |
| Haemoglobin decreased | 26.41 | 13.62 | 119 | 24926 | 248608 | 110315646 |
| Blood cholesterol increased | 26.25 | 13.62 | 5 | 25040 | 184780 | 110379474 |
| Haemorrhagic diathesis | 26.18 | 13.62 | 18 | 25027 | 7490 | 110556764 |
| Contraindicated product administered | 25.73 | 13.62 | 12 | 25033 | 248255 | 110315999 |
| Rash erythematous | 25.60 | 13.62 | 57 | 24988 | 81775 | 110482479 |
| Thrombotic microangiopathy | 25.13 | 13.62 | 32 | 25013 | 29117 | 110535137 |
| Circulatory collapse | 24.87 | 13.62 | 39 | 25006 | 42954 | 110521300 |
| Anaemia | 24.33 | 13.62 | 209 | 24836 | 546877 | 110017377 |
| Alanine aminotransferase increased | 24.26 | 13.62 | 94 | 24951 | 183679 | 110380575 |
| Emphysema | 24.24 | 13.62 | 26 | 25019 | 19730 | 110544524 |
| Musculoskeletal stiffness | 24.05 | 13.62 | 17 | 25028 | 279805 | 110284449 |
| Haemorrhage intracranial | 23.71 | 13.62 | 31 | 25014 | 28938 | 110535316 |
| Fibromyalgia | 23.50 | 13.62 | 5 | 25040 | 170904 | 110393350 |
| Arterial haemorrhage | 23.10 | 13.62 | 13 | 25032 | 3806 | 110560448 |
| Uterine disorder | 22.96 | 13.62 | 11 | 25034 | 2315 | 110561939 |
| Depression | 22.71 | 13.62 | 23 | 25022 | 317312 | 110246942 |
| Basophil count increased | 22.36 | 13.62 | 10 | 25035 | 1800 | 110562454 |
| Perforation | 22.36 | 13.62 | 10 | 25035 | 1800 | 110562454 |
| Multiple organ dysfunction syndrome | 22.02 | 13.62 | 80 | 24965 | 151630 | 110412624 |
| Lower respiratory tract infection | 21.92 | 13.62 | 14 | 25031 | 243092 | 110321162 |
| Sinusitis | 21.81 | 13.62 | 21 | 25024 | 296667 | 110267587 |
| Helicobacter infection | 21.81 | 13.62 | 7 | 25038 | 181870 | 110382384 |
| Tryptase decreased | 21.65 | 13.62 | 4 | 25041 | 25 | 110564229 |
| Toxicity to various agents | 21.61 | 13.62 | 48 | 24997 | 480507 | 110083747 |
| Embolic stroke | 21.54 | 13.62 | 17 | 25028 | 8726 | 110555528 |
| Puncture site haematoma | 21.49 | 13.62 | 6 | 25039 | 268 | 110563986 |
| Gastrooesophageal reflux disease | 21.45 | 13.62 | 7 | 25038 | 179969 | 110384285 |
| Procedural haemorrhage | 21.29 | 13.62 | 14 | 25031 | 5413 | 110558841 |
| Peripheral swelling | 21.06 | 13.62 | 37 | 25008 | 403997 | 110160257 |
| Ill-defined disorder | 20.74 | 13.62 | 5 | 25040 | 156848 | 110407406 |
| Night sweats | 20.42 | 13.62 | 3 | 25042 | 133980 | 110430274 |
| Chronic pulmonary histoplasmosis | 20.10 | 13.62 | 3 | 25042 | 3 | 110564251 |
| Inhibiting antibodies positive | 20.10 | 13.62 | 3 | 25042 | 3 | 110564251 |
| Acute left ventricular failure | 20.07 | 13.62 | 10 | 25035 | 2291 | 110561963 |
| Neurotoxicity | 20.00 | 13.62 | 35 | 25010 | 42172 | 110522082 |
| Enterocolitis | 19.91 | 13.62 | 23 | 25022 | 18926 | 110545328 |
| Acute myeloid leukaemia | 19.90 | 13.62 | 33 | 25012 | 38077 | 110526177 |
| Pyrexia | 19.77 | 13.62 | 299 | 24746 | 897966 | 109666288 |
| Nosocomial infection | 19.65 | 13.62 | 11 | 25034 | 3188 | 110561066 |
| Impaired healing | 19.63 | 13.62 | 10 | 25035 | 196707 | 110367547 |
| Therapeutic product effect decreased | 19.51 | 13.62 | 16 | 25029 | 244300 | 110319954 |
| Coagulopathy | 19.48 | 13.62 | 34 | 25011 | 40877 | 110523377 |
| Clonus | 19.46 | 13.62 | 16 | 25029 | 8700 | 110555554 |
| Loss of personal independence in daily activities | 19.41 | 13.62 | 5 | 25040 | 150015 | 110414239 |
| Condition aggravated | 19.41 | 13.62 | 93 | 24952 | 734743 | 109829511 |
| Infusion site warmth | 19.39 | 13.62 | 9 | 25036 | 1764 | 110562490 |
| Puncture site haemorrhage | 19.37 | 13.62 | 7 | 25038 | 725 | 110563529 |
| Type 2 diabetes mellitus | 19.26 | 13.62 | 8 | 25037 | 177224 | 110387030 |
| Gingival bleeding | 19.06 | 13.62 | 23 | 25022 | 19816 | 110544438 |
| Atrial thrombosis | 19.00 | 13.62 | 12 | 25033 | 4334 | 110559920 |
| Hepatic enzyme increased | 18.98 | 13.62 | 27 | 25018 | 320865 | 110243389 |
| Pleural effusion | 18.84 | 13.62 | 85 | 24960 | 177624 | 110386630 |
| Thoracotomy | 18.69 | 13.62 | 5 | 25040 | 190 | 110564064 |
| Haemophilic arthropathy | 18.16 | 13.62 | 5 | 25040 | 212 | 110564042 |
| Parenteral nutrition | 17.96 | 13.62 | 7 | 25038 | 893 | 110563361 |
| Wound | 17.93 | 13.62 | 16 | 25029 | 234421 | 110329833 |
| Extravasation | 17.81 | 13.62 | 12 | 25033 | 4833 | 110559421 |
| Urine ketone body present | 17.77 | 13.62 | 11 | 25034 | 3835 | 110560419 |
| Liver injury | 17.66 | 13.62 | 6 | 25039 | 150407 | 110413847 |
| Therapeutic product effect incomplete | 17.45 | 13.62 | 15 | 25030 | 223790 | 110340464 |
| Nasopharyngitis | 17.23 | 13.62 | 40 | 25005 | 394321 | 110169933 |
| Osteoarthritis | 17.18 | 13.62 | 10 | 25035 | 182613 | 110381641 |
| Pain in extremity | 17.10 | 13.62 | 55 | 24990 | 487063 | 110077191 |
| Heparin resistance | 17.06 | 13.62 | 5 | 25040 | 266 | 110563988 |
| Fibroma | 17.03 | 13.62 | 7 | 25038 | 1025 | 110563229 |
| Mouth haemorrhage | 16.99 | 13.62 | 18 | 25027 | 13470 | 110550784 |
| Urticaria | 16.98 | 13.62 | 127 | 24918 | 318730 | 110245524 |
| Cholestasis | 16.97 | 13.62 | 42 | 25003 | 64476 | 110499778 |
| Venoocclusive liver disease | 16.90 | 13.62 | 19 | 25026 | 15188 | 110549066 |
| Gastrointestinal disorder | 16.78 | 13.62 | 18 | 25027 | 241934 | 110322320 |
| Disseminated intravascular coagulation | 16.73 | 13.62 | 32 | 25013 | 41254 | 110523000 |
| Intracardiac thrombus | 16.72 | 13.62 | 11 | 25034 | 4257 | 110559997 |
| Intentional product use issue | 16.59 | 13.62 | 19 | 25026 | 247887 | 110316367 |
| Arthralgia | 16.58 | 13.62 | 106 | 24939 | 779526 | 109784728 |
| Blood bilirubin increased | 16.46 | 13.62 | 46 | 24999 | 75926 | 110488328 |
| Anti factor VIII antibody positive | 16.38 | 13.62 | 4 | 25041 | 105 | 110564149 |
| Haemophilia | 16.34 | 13.62 | 4 | 25041 | 106 | 110564148 |
| Cancer pain | 16.32 | 13.62 | 13 | 25032 | 6759 | 110557495 |
| Weight decreased | 16.32 | 13.62 | 53 | 24992 | 468004 | 110096250 |
| Bronchial artery embolisation | 16.21 | 13.62 | 3 | 25042 | 19 | 110564235 |
| Hospitalisation | 16.19 | 13.62 | 6 | 25039 | 142487 | 110421767 |
| Haemorrhagic disorder | 16.17 | 13.62 | 8 | 25037 | 1805 | 110562449 |
| Sepsis | 16.10 | 13.62 | 128 | 24917 | 327218 | 110237036 |
| Hepatic cyst ruptured | 16.07 | 13.62 | 3 | 25042 | 20 | 110564234 |
| Infusion site discomfort | 16.07 | 13.62 | 8 | 25037 | 1829 | 110562425 |
| Traumatic haemorrhage | 16.04 | 13.62 | 8 | 25037 | 1836 | 110562418 |
| Spontaneous haemorrhage | 15.97 | 13.62 | 7 | 25038 | 1201 | 110563053 |
| Postpartum haemorrhage | 15.86 | 13.62 | 8 | 25037 | 1881 | 110562373 |
| Swelling | 15.83 | 13.62 | 35 | 25010 | 351006 | 110213248 |
| Urinary tract disorder | 15.78 | 13.62 | 12 | 25033 | 5832 | 110558422 |
| Pulmonary alveolar haemorrhage | 15.63 | 13.62 | 21 | 25024 | 20129 | 110544125 |
| Rectal haemorrhage | 15.57 | 13.62 | 61 | 24984 | 119772 | 110444482 |
| Fall | 15.56 | 13.62 | 77 | 24968 | 603405 | 109960849 |
| PCO2 abnormal | 15.47 | 13.62 | 4 | 25041 | 133 | 110564121 |
| Pulseless electrical activity | 15.40 | 13.62 | 19 | 25026 | 16738 | 110547516 |
| Premature delivery | 15.30 | 13.62 | 26 | 25019 | 30606 | 110533648 |
| HER2 positive breast cancer | 15.23 | 13.62 | 5 | 25040 | 388 | 110563866 |
| Allergic reaction to excipient | 15.19 | 13.62 | 6 | 25039 | 793 | 110563461 |
| Myelodysplastic syndrome | 15.13 | 13.62 | 29 | 25016 | 37455 | 110526799 |
| Sinus tachycardia | 15.06 | 13.62 | 32 | 25013 | 44461 | 110519793 |
| Platelet count abnormal | 15.01 | 13.62 | 12 | 25033 | 6270 | 110557984 |
| Ischaemia | 14.91 | 13.62 | 14 | 25031 | 9069 | 110555185 |
| Neuromuscular blocking therapy | 14.90 | 13.62 | 3 | 25042 | 31 | 110564223 |
| Adnexal torsion | 14.72 | 13.62 | 5 | 25040 | 431 | 110563823 |
| Uterine leiomyoma | 14.72 | 13.62 | 13 | 25032 | 7787 | 110556467 |
| Fibrin degradation products increased | 14.71 | 13.62 | 5 | 25040 | 432 | 110563822 |
| Arterial thrombosis | 14.61 | 13.62 | 9 | 25036 | 3110 | 110561144 |
| Cyanosis | 14.53 | 13.62 | 25 | 25020 | 29716 | 110534538 |
| Memory impairment | 14.40 | 13.62 | 14 | 25031 | 196930 | 110367324 |
| Haematoma | 14.27 | 13.62 | 37 | 25008 | 58439 | 110505815 |
| Obesity | 14.24 | 13.62 | 4 | 25041 | 113347 | 110450907 |
| Infusion site rash | 14.24 | 13.62 | 8 | 25037 | 2335 | 110561919 |
| Psoriasis | 14.14 | 13.62 | 7 | 25038 | 139986 | 110424268 |
| Device related infection | 14.05 | 13.62 | 29 | 25016 | 39490 | 110524764 |
| Intentional self-injury | 13.94 | 13.62 | 28 | 25017 | 37401 | 110526853 |
| Pneumonia | 13.91 | 13.62 | 277 | 24768 | 876437 | 109687817 |
| Neutrophil count decreased | 13.69 | 13.62 | 59 | 24986 | 120882 | 110443372 |
| Ventricular tachycardia | 13.63 | 13.62 | 33 | 25012 | 49976 | 110514278 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B02AA02 | BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS ANTIFIBRINOLYTICS Amino acids |
| MeSH PA | D000933 | Antifibrinolytic Agents |
| MeSH PA | D003029 | Coagulants |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D006490 | Hemostatics |
| FDA PE | N0000175632 | Decreased Fibrinolysis |
| FDA EPC | N0000175634 | Antifibrinolytic Agent |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:48675 | antifibrinolytic drug |
| CHEBI has role | CHEBI:50248 | hematologic agent |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
B02AA Amino acids 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Contraception | indication | 13197004 | |
| Female hypogonadism syndrome | indication | 16041008 | |
| Endometriosis | indication | 129103003 | |
| Menorrhagia | indication | 386692008 | |
| Hemorrhaging in Hemophilia | indication | ||
| Refractory melasma | off-label use | 36209000 | |
| Epistaxis | off-label use | 249366005 | |
| Hyperfibrinolysis Induced Hemorrhage | off-label use | ||
| Prevention of Hemorrhage with Cardiovascular Instability from Cardiopulmonary Bypass - CABG | off-label use | ||
| Postsurgical Hemorrhage | off-label use | ||
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Cerebral edema | contraindication | 2032001 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Subarachnoid intracranial hemorrhage | contraindication | 21454007 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Depressive disorder | contraindication | 35489007 | |
| Migraine | contraindication | 37796009 | DOID:6364 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Body fluid retention | contraindication | 43498006 | |
| Thrombosis of retinal vein | contraindication | 46085004 | |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Benign mammary dysplasia | contraindication | 57993004 | |
| Obstructive hyperbilirubinemia | contraindication | 59848001 | |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Intermenstrual bleeding - irregular | contraindication | 64996003 | |
| Cerebral arterial thrombosis | contraindication | 71444005 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Malignant neoplasm of liver | contraindication | 93870000 | DOID:3571 |
| Deep venous thrombosis | contraindication | 128053003 | |
| Angina pectoris | contraindication | 194828000 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Pulmonary thromboembolism | contraindication | 233935004 | |
| Thrombophilia | contraindication | 234467004 | DOID:2452 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cholestasis of pregnancy | contraindication | 235888006 | |
| Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Malignant tumor of cervix | contraindication | 363354003 | DOID:4362 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Ligneous conjunctivitis | contraindication | 403435005 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Estrogen receptor positive tumor | contraindication | 416053008 | |
| Porphyria | contraindication | 418470004 | |
| Thrombosis | contraindication | 439127006 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Major Surgery with Prolonged Post-Operative Immobilization | contraindication | ||
| Nonspecific Abnormal Papanicolaou Smear of Cervix | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.31 | acidic |
| pKa2 | 10.7 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Plasminogen | Enzyme | INHIBITOR | Kd | 5.96 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020569 | VUID |
| N0000148271 | NUI |
| D01136 | KEGG_DRUG |
| 4020569 | VANDF |
| C0040613 | UMLSCUI |
| CHEBI:48669 | CHEBI |
| CHEMBL877 | ChEMBL_ID |
| DB00302 | DRUGBANK_ID |
| D014148 | MESH_DESCRIPTOR_UI |
| 5526 | PUBCHEM_CID |
| 2060 | INN_ID |
| 6573 | IUPHAR_LIGAND_ID |
| 6T84R30KC1 | UNII |
| 10691 | RXNORM |
| 5607 | MMSL |
| 80873 | MMSL |
| d00529 | MMSL |
| 002073 | NDDF |
| 109006003 | SNOMEDCT_US |
| 386960009 | SNOMEDCT_US |
| 6T84R30KC1 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cyklokapron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0013-1114 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 30 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-0960 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3720 | TABLET, FILM COATED | 650 mg | ORAL | ANDA | 25 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14593-318 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | ANDA | 2 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-115 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 26 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-166 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-524 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-909 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 18 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-910 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 18 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-415 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-415 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-418 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-1000 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 31 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-189 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-314 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-008 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 27 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43066-008 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 27 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4530 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-772 | TABLET | 650 mg | ORAL | NDA authorized generic | 28 sections |
| TRANEXAMIC ACID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1532 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 16 sections |
| TRANEXAMIC ACID IN SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-0108 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | NDA | 25 sections |
| Tranexamic Acid | Human Prescription Drug Label | 1 | 55150-188 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| TRANEXAMIC ACID | Human Prescription Drug Label | 1 | 59651-839 | TABLET | 650 mg | ORAL | ANDA | 27 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6169 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 28 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-750 | TABLET | 650 mg | ORAL | ANDA | 29 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-265 | TABLET | 650 mg | ORAL | ANDA | 29 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8599 | TABLET, FILM COATED | 650 mg | ORAL | ANDA | 26 sections |
| Tranexamic Acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8838 | TABLET, FILM COATED | 650 mg | ORAL | ANDA | 26 sections |
| Tranexamic Acid | Human Prescription Drug Label | 1 | 65145-106 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 27 sections |
| TRANEXAMIC ACID IN SODIUM CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-534 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 26 sections |